A Randomized, Placebo-Controlled, Double-Blind, Crossover, Single-Dose Exposure Study to Evaluate the Early Bronchodilating Effect of FlutiForm 100/10 microg HFA pMDI and FlutiForm 250/10 microg HFA pMDI, Compared to Placebo in Adult Subjects With Mild to Moderate Asthma.

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Crossover, Single-Dose Exposure Study to Evaluate the Early Bronchodilating Effect of FlutiForm 100/10 microg HFA pMDI and FlutiForm 250/10 microg HFA pMDI, Compared to Placebo in Adult Subjects With Mild to Moderate Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2010

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors SkyePharma AG
  • Most Recent Events

    • 11 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 11 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top